Al's Comment:

 This is an exciting new treatment. The Musella Foundation helped fund part of it. OS2966 is a brand new class of treatment, which targets CD29/B1 integrins which are highly upregulated in Glioblastomas and have been shown to drive tumor progression and invasion as well as participate in the resistance pathways.  

Posted on: 03/19/2021

Convection-Enhanced Delivery of a First-in-Class Anti-B1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging


Click HERE to return to brain tumor news headlines.